A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
Status:
Completed
Trial end date:
2019-07-16
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to assess the safety profile, characterize
pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and
the recommended phase two dose (RPTD) of ABT-199 when administered in subjects with relapsed
/refactory multiple myeloma who are receiving bortezomib and dexamethasone as their standard
therapy.